Potent (AC50 = 0.111µM) and selective (over PKM1, PKR and PKL) activator of the tumor cell specific M2 isoform of pyruvate kinase (PKM2). Pyruvate kinase is a potential target for cancer chemotherapy. A useful new tool for altering aberrant glucose metabolism in cancer cells (Warburg effect).
Product Details
| Alternative Name: | NCGC00030335, 1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-ylsulfonyl)-4-(4-methoxyphenylsulfonyl)-piperazine |
| |
| Formula: | C19H22N2O7S2 |
| |
| MW: | 454.5 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | White solid. |
| |
| MeltingPoint: | 229-231°C |
| |
| Solubility: | Soluble in DMSO (12mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Use/Stability: | Store, as supplied, at room temperature for up to one year. Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Evaluation of Substituted N,N'-Diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase: M. Boxer, et al.; J. Med. Chem.
53, 1048 (2010),
Abstract;
